Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623636 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of MAP0004 in Adult Migraineurs
A Phase 3 study of Migraine Disorders, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
- 1
- Study location
NCT00623636 is a Phase 3 study of Migraine Disorders that has completed, run by Allergan. The registered enrollment target is 902 participants, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (232% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00623636, a Phase 3 study of Migraine Disorders, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAP0004
Study Locations (1)
Washington
- Swedish Pain and Headache Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623636
The ClinicalTrials.gov registry entry for NCT00623636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (232% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00623636 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00623636 about?
NCT00623636 is a clinical study titled "Phase 3 Study of MAP0004 in Adult Migraineurs". This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.
What is the current status of trial NCT00623636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2008-07. Estimated completion is 2011-01.
What conditions does trial NCT00623636 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00623636?
The interventions under investigation include: Placebo (DRUG), MAP0004 (DRUG).
Who is sponsoring clinical trial NCT00623636?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623636 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.